Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in ...

BioNTech (BNTX) stock tumbles 17% after reporting Q4 losses, missing 2026 revenue projections, and announcing co-founder departures. Full analysis here.

There's no easy way to identify the most hated stocks on Wall Street, but looking at the activity of short sellers is a great place to start. Short selling is a difficult art that involves ...

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on RegenXBio today and set a price target of $25.00. According to TipRanks, Stranahan is a 4-star analyst with an average ...

However, the vaccine manufacturers concerned may appeal against this decision in order to protect their professional, commercial and manufacturing secrets, the Federal Office of P ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

Commissioner Marty Makary on Friday announced that the agency’s top regulator Vinay Prasad will depart next month. “A year ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 2:30 PM ESTCompany ParticipantsJohn Jacobs - President, CEO ...

Novavax’s modeled fair value has been reset to US$13.78 from US$13.11, a small move that still matters if you are tracking how assumptions are shifting. Behind that change, recent Street research ...

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Hold rating on Xencor, with a price target of $19.00.

Novavax Inc. (NASDAQ: NVAX) shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 ...

NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67 ...